Protagonist Therapeutics Inc (PTGX) is expecting 88.10% growth in the next quarter: What can investors do to maximize their returns?

QCOM

Protagonist Therapeutics Inc (NASDAQ: PTGX) kicked off on Monday, up 5.99% from the previous trading day, before settling in for the closing price of $26.69. Over the past 52 weeks, PTGX has traded in a range of $13.72-$30.10.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 3046.64%. While this was happening, its average annual earnings per share was recorded 22.58%. With a float of $54.13 million, this company’s outstanding shares have now reached $57.68 million.

Protagonist Therapeutics Inc (PTGX) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Protagonist Therapeutics Inc is 6.16%, while institutional ownership is 95.70%. The most recent insider transaction that took place on Jan 09, was worth 125,000. In this transaction Chief Development Officer of this company sold 5,000 shares at a rate of $25.00, taking the stock ownership to the 187,567 shares. Before that another transaction happened on Dec 13, when Company’s President and CEO sold 75,000 for $20.08, making the entire transaction worth $1,506,000. This insider now owns 534,347 shares in total.

Protagonist Therapeutics Inc (PTGX) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 28.29 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 22.58% per share during the next fiscal year.

Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators

Take a look at Protagonist Therapeutics Inc’s (PTGX) current performance indicators. Last quarter, stock had a quick ratio of 11.66.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.79 in one year’s time.

Technical Analysis of Protagonist Therapeutics Inc (PTGX)

Looking closely at Protagonist Therapeutics Inc (NASDAQ: PTGX), its last 5-days average volume was 0.69 million, which is a drop from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 47.56%. Additionally, its Average True Range was 1.41.

During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 91.46%, which indicates a significant increase from 75.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.20% in the past 14 days, which was higher than the 55.21% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $23.32, while its 200-day Moving Average is $21.23. However, in the short run, Protagonist Therapeutics Inc’s stock first resistance to watch stands at $28.87. Second resistance stands at $29.45. The third major resistance level sits at $30.49. If the price goes on to break the first support level at $27.25, it is likely to go to the next support level at $26.21. Should the price break the second support level, the third support level stands at $25.63.

Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats

The company with the Market Capitalisation of 1.63 billion has total of 57,678K Shares Outstanding. Its annual sales at the moment are 26,580 K in contrast with the sum of -127,390 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -34,110 K.